Pacira Biosciences, Inc. reiterated earnings guidance for the full year 2024. For the period, the company expects total revenue of $680 million to $705 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.51 USD | -1.23% | +2.76% | -9.57% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.57% | 1.44B | |
+42.83% | 748B | |
+34.11% | 598B | |
-5.70% | 356B | |
+18.06% | 325B | |
+4.63% | 283B | |
+17.02% | 245B | |
+9.26% | 211B | |
-4.21% | 209B | |
+2.43% | 166B |
- Stock Market
- Equities
- PCRX Stock
- News Pacira BioSciences, Inc.
- Pacira Biosciences, Inc. Reiterates Earnings Guidance for the Full Year 2024